No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Healthcare Information Services
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
www.airdoc.comNo one on the platform currently holds 2251.HK.
No tracked institution reports a position in 2251.HK as of their last filing.
No one on the platform has traded 2251.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 10.8% | 29.4% | ||||
| Profit Margin % | -14.4% | -105.0% | ||||
| Free Cash Flow Margin % | -12.2% | -116.5% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $294M | +32.8% | $-0.43 | $-0.43–$-0.43 | — | 1 |
| 2027 | $1.0B | +241.0% | $0.85 | $0.85–$0.85 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2251.HKBeijing Airdoc Technology Co., Ltd. | $9.00 | +1.29% | $909M | — |
| 1244.HK3D Medicines Inc. | $2.34 | -0.85% | $575M | — |
| 2137.HKBrii Biosciences Limited | $0.86 | -1.71% | $620M | — |
| 2216.HKBroncus Holding Corporation | $0.65 | +2.36% | $342M | — |
| 2407.HKGaush Meditech Ltd | $4.80 | +3.23% | $710M | — |
| 2496.HKWuhan YZY Biopharma Co Ltd | $3.30 | -8.33% | $662M | — |
| 2500.HKVenus Medtech (Hangzhou) Inc. | $1.14 | +3.64% | $503M | — |
Source: Financial Modeling Prep · peers by sector/industry